Collectively, these data suggest that mitochondrial ER-β is a target for endocrine therapy agents in breast cancer cells lacking ER-α expression and mitochondrial ER-β and ER-α differentially regulate response to endocrine therapy and mitochondrial priming. The gene discussed is ESR1; the disease is breast cancer.